Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. (Q36388364)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

review article

1 reference

title

Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Fabien Zoulim

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

7

Christian Trepo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Sandra Carrouée-Durantel

4

object named as

Sandra Carrouée-Durantel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Marie-Noelle Brunelle

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Edwige Gros

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Christian Pichoud

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Stephanie Villet

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

1 December 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Virology

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

34 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

S34-43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Hepatitis B virus genotypes: comparison of genotyping methods

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Molecular genotyping of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

1 reference

7 January 2021

Antiviral drugs in current clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Hepatitis B virus: old, new and future approaches to antiviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Entecavir for the treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Clinical trial results and treatment resistance with lamivudine in hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Detection of hepatitis B virus resistance to antivirals

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Hepatitis B virus resistance to antivirals: clinical implications and management.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980008-3

7 January 2021

10.1016/S1386-6532(05)80008-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461221%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference